Antibiotics do not lower Avastin infection risk

Article

The incidence of endophthalmitis is independent of whether prophylactic antibiotics are administered in conjunction with Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Prophylactic antibiotics do not lower the incidence of endophthalmitis in patients receiving Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Carsten H. Meyer, MD of the Augenklinik at Bonn University, Germany and colleagues conducted a retrospective study of two groups of patients receiving 1.25 mg/0.05 ml Avastin after an incubation of 5% povidone-iodine for 60 seconds in the conjunctival fornix. The first set of subjects (Group A; n=984) underwent the injection as an outpatient procedure and received no prophylactic antibiotics after the injection. In the second set (Group B; n=860), patients were admitted to hospital for one day and received three days of topical antibiotics following the injection.

The subjects of Group A had a zero incidence of post-injection endophthalmitis; two patients developed intraocular uveitis, which was treated successfully with topical steroids. In Group B, the two cases of post-injection endophthalmitis that developed after five days were treated with vitrectomy.

The researchers concluded that administration of prophylactic antibiotics was unable to eliminate endophthalmitis in these cases; when considering this factor, it is irrelevant whether the injection of Avastin is administered on an inpatient or outpatient basis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.